The International Myeloma Foundation is dedicated to improving the lives of multiple myeloma patients while working toward
prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
The goal of this activity is to increase the knowledge and competence of hematologists/oncologists and other clinicians who care for patients with multiple myeloma in the areas of treatment selection for transplant-ineligible patients, maintenance therapy, and management of therapy-related adverse events.
The Phase 3 TOURMALINE-MM4 study has met its primary endpoint of progression free survival (PFS). "The trial evaluated the effect of single-agent oral NINLARO™ (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation."
Details about co-pay assistance programs for multiple myeloma patients.
Once again, the IMF will bring myeloma support group leaders and patients to the annual meeting of the American Society of Hematology (ASH). Visit this site to learn what these IMF ASH team members have to share about the latest clinical updates in myeloma research and treatment strategies.
Launched three years ago, the iStopMM project is assessing the impact and outcomes from early screening for MGUS, smoldering myeloma, and active myeloma for the whole of Iceland.
In this week’s video, Dr. Durie explains what a "BEAT" is, and how it is similar to a BiTE.
Need to stay informed about the news that impacts myeloma patients, but don’t have time to read everything out there? Then be sure to follow Dr. Brian Durie’s Week in Review blog. The leading myeloma expert and IMF Chairman of the Board drills down on a wide range of topics – from the latest myeloma research results to the environmental issues that offer insight into prevention. He sifts through the data to deliver the bottom line.
The support of loved ones allows us to continue to fund efforts to search for a cure. Check out how Fundraisers are helping in the fight against myeloma.
